[go: up one dir, main page]

WO1999035243A3 - Extension of cellular lifespan, methods and reagents - Google Patents

Extension of cellular lifespan, methods and reagents Download PDF

Info

Publication number
WO1999035243A3
WO1999035243A3 PCT/US1999/000682 US9900682W WO9935243A3 WO 1999035243 A3 WO1999035243 A3 WO 1999035243A3 US 9900682 W US9900682 W US 9900682W WO 9935243 A3 WO9935243 A3 WO 9935243A3
Authority
WO
WIPO (PCT)
Prior art keywords
reagents
methods
extension
vivo
cellular lifespan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/000682
Other languages
French (fr)
Other versions
WO1999035243A9 (en
WO1999035243A2 (en
Inventor
Gregory J Hannon
Jing Wang
David H Beach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Priority to JP2000527629A priority Critical patent/JP2002500040A/en
Priority to AU23172/99A priority patent/AU759437B2/en
Priority to IL13710199A priority patent/IL137101A0/en
Priority to EP99903059A priority patent/EP1045697A2/en
Priority to CA002315265A priority patent/CA2315265A1/en
Publication of WO1999035243A2 publication Critical patent/WO1999035243A2/en
Publication of WO1999035243A3 publication Critical patent/WO1999035243A3/en
Publication of WO1999035243A9 publication Critical patent/WO1999035243A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods and reagents for extending the life-span, e.g., the number of mitotic divisions, of a cell. In general, the subject method relies on the ectopic expression of the telomerase catalytic subunit EST2, or a bioactive fragment thereof. The subject method is useful both in vivo, ex vivo and in situ.
PCT/US1999/000682 1998-01-12 1999-01-12 Extension of cellular lifespan, methods and reagents Ceased WO1999035243A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000527629A JP2002500040A (en) 1998-01-12 1999-01-12 Extending cell life, methods and reagents
AU23172/99A AU759437B2 (en) 1998-01-12 1999-01-12 Extension of cellular lifespan, methods and reagents
IL13710199A IL137101A0 (en) 1998-01-12 1999-01-12 Extension of cellular lifespan, methods and reagents
EP99903059A EP1045697A2 (en) 1998-01-12 1999-01-12 Extension of cellular lifespan, methods and reagents
CA002315265A CA2315265A1 (en) 1998-01-12 1999-01-12 Extension of cellular lifespan, methods and reagents

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7122098P 1998-01-12 1998-01-12
US7145598P 1998-01-13 1998-01-13
US6365798A 1998-04-21 1998-04-21
US09/063,657 1998-04-21
US60/071,220 1998-04-21
US60/071,455 1998-04-21

Publications (3)

Publication Number Publication Date
WO1999035243A2 WO1999035243A2 (en) 1999-07-15
WO1999035243A3 true WO1999035243A3 (en) 1999-09-16
WO1999035243A9 WO1999035243A9 (en) 1999-10-28

Family

ID=27370514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000682 Ceased WO1999035243A2 (en) 1998-01-12 1999-01-12 Extension of cellular lifespan, methods and reagents

Country Status (6)

Country Link
EP (1) EP1045697A2 (en)
JP (1) JP2002500040A (en)
AU (1) AU759437B2 (en)
CA (1) CA2315265A1 (en)
IL (1) IL137101A0 (en)
WO (1) WO1999035243A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846904B2 (en) 2003-06-23 2010-12-07 Geron Corporation Compositions and methods for increasing telomerase activity
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572845B2 (en) * 1998-10-16 2003-06-03 Burt D. Ensley Recombinant hair treatment compositions
JP2002530436A (en) * 1998-11-25 2002-09-17 ジェネティカ インコーポレイテッド Method and reagent for enhancing proliferation ability and preventing replication senescence
CA2852534A1 (en) 1999-08-05 2001-02-15 Abt Holding Company Multipotent adult stem cells and methods for isolation
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
AU2006202072B2 (en) * 1999-08-05 2010-12-09 Abt Holding Company Multipotent adult stem cells and methods for isolation
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
EP1103615A1 (en) * 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
FR2810046B1 (en) * 2000-06-07 2004-09-10 Neurotech PROCESS FOR CONDITIONAL IMMORTALIZATION OF CELLS AND PROTEIN CONSTRUCTIONS FOR ITS IMPLEMENTATION
US20020045219A1 (en) * 2000-08-02 2002-04-18 Whitehead Institute For Biomedical Research Production of human monoclonal antibodies
US6686159B2 (en) 2000-08-24 2004-02-03 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression
EP1367899A4 (en) 2001-02-14 2004-07-28 Leo T Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
AU2002345743A1 (en) 2001-06-21 2003-01-08 Sierra Sciences, Inc. Telomerase expression repressor proteins and methods of using the same
WO2003066839A1 (en) * 2002-02-05 2003-08-14 Rappaport Family Institute For Research In The Medical Sciences Lineage committed stem cells selected for telomerase promoter activity
US20060228798A1 (en) 2002-11-27 2006-10-12 Catherine Verfaillie Homologous recombination in multipotent adult progenitor cells
US8426200B2 (en) 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
WO2007047509A2 (en) 2005-10-14 2007-04-26 Regents Of The University Of Minnesota Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
AU2007321928A1 (en) 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
CN101978047A (en) 2008-01-18 2011-02-16 明尼苏达大学董事会 Stem cell aggregates and methods for making and using
EP2362899A1 (en) 2008-10-31 2011-09-07 Katholieke Universiteit Leuven Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells
HUE036081T2 (en) 2009-03-09 2018-06-28 Bioatla Llc Mirac Proteins
PL2437606T3 (en) 2009-05-18 2017-07-31 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
LT2536830T (en) 2010-02-16 2019-11-11 Ultimovacs Asa POLYPEPTIDIDES
SG185526A1 (en) 2010-05-12 2012-12-28 Abt Holding Co Modulation of splenocytes in cell therapy
US9090878B2 (en) 2010-06-17 2015-07-28 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
ES2590461T3 (en) * 2010-07-02 2016-11-22 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Telomerase reverse transcriptase as protection against aging
EP2609191B1 (en) 2010-08-24 2017-11-22 Regents Of The University Of Minnesota Non-static suspension culture of cell aggregates
PL2983680T3 (en) 2013-04-12 2021-03-08 Houston Methodist Hospital Improving organs for transplantation
CN114657281A (en) * 2020-12-22 2022-06-24 中国科学院动物研究所 Endogenous virus as marker of aging degree and application of endogenous virus as aging intervention target
CN114601747A (en) * 2022-03-07 2022-06-10 广州市万千粉丝化妆品有限公司 Application of nucleoprotein telomerase with functions of promoting growth of protein and RNA, prolonging cell telomere and proliferating in cosmetics
WO2024075819A1 (en) * 2022-10-07 2024-04-11 Ａｇｃ株式会社 Virus vector production method employing cell

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013382A1 (en) * 1993-11-12 1995-05-18 Geron Corporation Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
WO1996040868A1 (en) * 1995-06-07 1996-12-19 Cold Spring Harbor Laboratory Essential oligonucleotides of vertebrate telomerase
US5830644A (en) * 1992-05-13 1998-11-03 Geron Corporation Method for screening for agents which increase telomerase activity in a cell

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830644A (en) * 1992-05-13 1998-11-03 Geron Corporation Method for screening for agents which increase telomerase activity in a cell
WO1995013382A1 (en) * 1993-11-12 1995-05-18 Geron Corporation Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
WO1996040868A1 (en) * 1995-06-07 1996-12-19 Cold Spring Harbor Laboratory Essential oligonucleotides of vertebrate telomerase

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AUTEXIER C ET AL: "RECONSTITUTION OF HUMAN TELOMERASE ACTIVITY AND IDENTIFICATION OF AMINIMAL FUNCTIONAL REGION OF THE HUMAN TELOMERASE RNA", EMBO JOURNAL, vol. 15, no. 21, 1 November 1996 (1996-11-01), pages 5928 - 5935, XP002056802 *
H. VAZIRI AND S. BENCHIMOL: "RECONSTITUTION OF TELOMERASE ACTIVITY IN NORMAL HUMAN CELLS LEADS TO ELONGATION OF TELOMERES AND EXTENDED REPLICATIVE LIFE SPAN", CURRENT BIOLOGY, vol. 8, no. 5, 26 February 1998 (1998-02-26), pages 279 - 282, XP002107653 *
J. WANG ET AL.: "MYC ACTIVATES TELOMERASE", GENES & DEVELOPMENT, vol. 12, 1998, pages 1769 - 1774, XP002107654 *
K. FUJIMOTO AND M. TAKAHASHI: "TELOMERASE ACTIVITY IN HUMAN LEUKEMIC CELL LINES IS INHIBITED BY ANTISENSE PENTADECADEOXYNUCLEOTIDES TARGETED AGAINST C-MYC MRNA", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 241, 1997, pages 775 - 781, XP002107655 *
K. HIYAMA ET AL.: "ACTIVATION OF TELOMERASE IN HUMAN LYMPHOCYTES AND HEMATOPOIETIC PROGENITOR CELLS", J. IMMUNOLOGY, vol. 155, no. 8, 1995, pages 3711 - 3715, XP002107651 *
S.L. WEINRICH ET AL.: "RECONSTITUTION OF HUMAN TELOMERASE WITH THE TEMPLATE RNA COMPONENT HTR AND THE CATALYTIC PROTEIN SUBUBIT HTRT", NATURE GENETICS, vol. 17, 1997, pages 498 - 502, XP002107652 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846904B2 (en) 2003-06-23 2010-12-07 Geron Corporation Compositions and methods for increasing telomerase activity
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning

Also Published As

Publication number Publication date
IL137101A0 (en) 2001-06-14
CA2315265A1 (en) 1999-07-15
AU759437B2 (en) 2003-04-17
WO1999035243A9 (en) 1999-10-28
EP1045697A2 (en) 2000-10-25
WO1999035243A2 (en) 1999-07-15
AU2317299A (en) 1999-07-26
JP2002500040A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
WO1999035243A3 (en) Extension of cellular lifespan, methods and reagents
WO2000031238A3 (en) Methods and reagents for increasing proliferative capacity and preventing replicative senescence
WO2002018638A3 (en) Detection of cyp2d6 polymorphisms
DE69917716D1 (en) Protein-deamidative enzyme, gene coding therefor, method for the production and use thereof
DE69939945D1 (en) METHOD OF ISOLATING STEM CELLS
IL141308A0 (en) Methods, instruments and materials for chondrocyte cell transplantation
EP1095207A4 (en) High temperature airfoil
AU6042699A (en) Assays for measuring nucleic acid binding proteins and enzyme activities
AU3199699A (en) Modified nucleotides and methods useful for nucleic acid sequencing
HUP9701341A3 (en) Modified thermostable dns polymerase, process for producing thereof, nucleic acid codind the enzyme, vector containing the nucleic acid, a composition containing thereof
WO1999067619A3 (en) Compounds and methods for detecting biomolecules
DE69839024D1 (en) Integrated resonant microstructure sensor for high temperatures
ID26690A (en) CATALYST COMPOSITION, THE METHOD OF MAKING IT AND THE METHOD OF PURIFICATION OF ACID
DE69501228D1 (en) Ascorbate oxidase, gene coding therefor, process for its preparation and reagent composition using the same
WO2004042006A3 (en) Amylases, nucleic acids encoding them and methods for making and using them
EP1102992A4 (en) Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis c virus protease
WO2003048308A3 (en) Thermus brockianus nucleic acid polymerases
AU2002352902A8 (en) Thermus thermophilus nucleic acid polymerases
AU6372099A (en) Method for the generation of dna fingerprints
AU2462399A (en) Cubilin protein, dna sequences encoding cubilin and uses thereof
EP1466013A4 (en) Thermus scotoductus nucleic acid polymerases
AU2002346517A1 (en) Thermus oshimai nucleic acid polymerases
DE69823174D1 (en) METHOD FOR CVD AT LOW TEMPERATURES USING BI-CARBOXYLATES
ATE256657T1 (en) 2,5-SUBSTITUTED BENZENESULFONYL UREASES AND THIOUREASES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMCEUTICAL PREPARATIONS CONTAINING THEM
GB2344591B (en) Thermostable DNA polymerase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 137101

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2315265

Country of ref document: CA

Ref country code: CA

Ref document number: 2315265

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 23172/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999903059

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 527629

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999903059

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999903059

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 23172/99

Country of ref document: AU